PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Neurology3 citations

Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children

View Full Paper
AMAmaar MarefiEGE GrassoLMLoren McLendon

Key Points

  • The aim is to evaluate the effectiveness of tocilizumab in treating severe CNS inflammatory presentations in children.
  • Class IV evidence study design
  • Assessment of clinical outcomes
  • Population involved children with acute-severe CNS inflammation
  • Tocilizumab improved clinical outcomes for children with severe CNS inflammation.
  • The findings suggest a positive therapeutic effect of tocilizumab on acute severe events.

Abstract

This study provides Class IV evidence that TCZ improves clinical outcomes in children with acute-severe CNS inflammatory events.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marefi et al. (2026) studied this question.

synapsesocial.com/papers/69d894526c1944d70ce0547bhttps://doi.org/10.1212/wnl.0000000000214926
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of early immunotherapy in rasmussen’s encephalitis2026 · 2 citations
  2. 2Life-Threatening MOG Antibody-Associated Hemorrhagic ADEM With Elevated CSF IL-62024 · 22 citations
  3. 3A case report and literature review on tocilizumab-cured acute necrotizing encephalopathy caused by influenza A virus2024 · 15 citations
  4. 4CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications2018 · 204 citations
  5. 5FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome2018 · 901 citations